🇺🇸 FDA
Patent

US 8278100

Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders

granted A61KA61K31/35A61K45/06

Quick answer

US patent 8278100 (Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/35, A61K45/06, A61P, A61P25/00